Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07261241 · ClinicalTrials.gov registry record · Phase 2
NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab
A Phase 2 study, sponsored by New Approaches to Neuroblastoma Therapy Consortium.
- Not yet
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
NCT07261241 is a Phase 2 study that has not yet begun recruiting, run by New Approaches to Neuroblastoma Therapy Consortium. The registered enrollment target is 118 participants.
The verdict
NCT07261241, a Phase 2 study, has not yet begun recruiting, sponsored by New Approaches to Neuroblastoma Therapy Consortium.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
Study Summary
Patients will then be randomized at study entry to one of three treatment arms. Patients on Arm A will receive a single treatment course with 131I-MIBG with vorinostat. Patients on Arm B will receive a single treatment course with 131I-MIBG and dinutuximab. Patients on Arm C will receive a single treatment course with 131I-MIBG with dinutuximab + vorinostat. After this course of treatment, we will check to see your response and then check to see how you are doing over time. All patients may choose to proceed to a second course of the same treatment if they and their physician feel healthy enough to do so. Approximately 118 patients will be receiving therapy on this trial.
Interventions
- DRUG Vorinostat
- DRUG Dinutuximab
- DRUG Radiation: 131I-MIBG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2026-07-31 |
| Est. Completion | 2031-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07261241
The ClinicalTrials.gov registry entry for NCT07261241 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Approaches to Neuroblastoma Therapy Consortium, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vorinostat is the first listed.
NCT07261241 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07261241 about?
NCT07261241 is a clinical study titled "NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab". Patients will then be randomized at study entry to one of three treatment arms. Patients on Arm A will receive a single treatment course with 131I-MIBG with vorinostat. Patients on Arm B will receive a single treatment course with 131I-MIBG and dinutuximab. Patients on Arm C will receive a single tr...
What is the current status of trial NCT07261241?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2026-07-31. Estimated completion is 2031-07-31.
What interventions are being tested in trial NCT07261241?
The interventions under investigation include: Vorinostat (DRUG), Dinutuximab (DRUG), Radiation: 131I-MIBG (DRUG).
Who is sponsoring clinical trial NCT07261241?
This trial is sponsored by New Approaches to Neuroblastoma Therapy Consortium, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.